Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis
Authors:
Top Cited Papers
- 9 March 2020
- journal article
- review article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 147 (2) , 297-307
Abstract
Introduction Despite aggressive treatment with chemoradiotherapy and maximum surgical resection, survival in patients with glioblastoma (GBM) remains poor. Ongoing efforts are aiming to prolong the lifespan of these patients; however, disparities exist in reported survival values with lack of clear evidence that objectively examines GBM survival trends. We aim to describe the current status and advances in the survival of patients with GBM, by analyzing median overall survival through time and between treatment modalities. Methods A systematic review was conducted according to PRISMA guidelines to identify articles of newly diagnosed glioblastoma from 1978 to 2018. Full-text glioblastoma papers with human subjects, ≥ 18 years old, and n ≥ 25, were included for evaluation. Results The central tendency of median overall survival (MOS) was 13.5 months (2.3–29.6) and cumulative 5-year survival was 5.8% (0.01%–29.1%), with a significant difference in survival between studies that predate versus postdate the implementation of temozolomide and radiation, [12.5 (2.3–28) vs 15.6 (3.8–29.6) months, P < 0.001]. In clinical trials, bevacizumab [18.2 (10.6–23.0) months], tumor treating fields (TTF) [20.7 (20.5–20.9) months], and vaccines [19.2 (15.3–26.0) months] reported the highest central measure of median survival. Conclusion Coadministration with radiotherapy and temozolomide provided a statistically significant increase in survival for patients suffering from glioblastoma. However, the natural history for GBM remains poor. Therapies including TTF pooled values of MOS and provide means of prolonging the survival of GBM patients.Keywords
This publication has 52 references indexed in Scilit:
- Persistent Disparities in Survival for Patients with GlioblastomaWorld Neurosurgery, 2018
- Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic ResistanceWorld Neurosurgery, 2018
- Ten-year survival in glioblastoma. A systematic reviewJournal of Clinical Neuroscience, 2018
- Survival of Ventricular and Periventricular High-Grade Gliomas: A Surveillance, Epidemiology, and End Results Program–Based StudyWorld Neurosurgery, 2018
- CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014Neuro-Oncology, 2017
- A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed GlioblastomaClinical Cancer Research, 2016
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III studyNeuro-Oncology, 2015
- A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regimeBritish Journal Of Neurosurgery, 2013
- NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modalityEuropean Journal of Cancer, 2012
- Supratentorial Glioblastoma Multiforme: The Role of Surgical Resection Versus Biopsy Among Older PatientsAnnals of Surgical Oncology, 2010